AB Science
Clinical trials sponsored by AB Science, explained in plain language.
Develops small-molecule kinase inhibitors for cancer and inflammatory diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
New drug masitinib could slow Alzheimer's decline
Disease control Not yet recruitingThis Phase 3 trial tests whether masitinib, a drug that targets immune cells in the brain, can slow cognitive decline in 600 people with mild Alzheimer's. Participants take masitinib or a placebo alongside standard Alzheimer's medications. The study lasts 24 weeks and measures ch…
Phase 3 • Sponsor: AB Science • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Promising ALS drug enters final testing phase
Disease control Not yet recruitingThis phase 3 trial tests whether adding masitinib to standard ALS treatment (riluzole) can slow the disease better than placebo plus riluzole. About 412 adults with ALS will take the drug or placebo for 48 weeks. The main goal is to measure changes in daily function and breathing…
Phase 3 • Sponsor: AB Science • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC